Background: The sequential occurrence of the 2 malignancies development of nasopharyngeal carcinoma (NPC) and lymphoma is extremely rare and their coexistence raises the question of a common etiologic factor.
Introduction
Nasopharyngeal carcinoma (NPC) is a rare malignancy that occurs worldwide with a marked geographic and racial variation in incidence. The major etiological factors proposed for NPC pathogenesis include genetic susceptibility, environment factors and Epstein-Barr virus (EBV) infection. [1] Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma. EBV-positive DLBCL of the elderly accounts for 8.7% to 11.4% of all DLBCL cases in Asian countries, but less than 5% in western nations. [2] EBV-positive patients, especially elderly patients, have an inferior prognosis compared with EBVnegative cases. [2] EBV is a ubiquitous human herpes virus infecting over 90% of the adult population worldwide. EBV has been classified as a group I carcinogen by the International Agency for Research on Cancer, with conclusive evidence with respect to carcinogenicity in NPC and in causing lymphoproliferative diseases, most of which are polyclonal B-cell proliferations classified as diffuse lymphomas. [3] Primary EBV infection usually occurs early in life and is asymptomatic; 95% of the adults latently harbor the virus within B cells. [2] Latent EBV infection is believed to be involved in tumorigenesis as lytic reactivation of EBV infection in infected cells will lead to cell death. [1] Latent EBV infection is associated with several lymphoid and epithelial malignancies.
There are some published case reports of patients who develop NPC and Hodgkin's lymphoma separated by several years or presenting concurrently at diagnosis. [4] Here, we describe the case of sequential presentation of NPC and DLBCL. Sequential occurrence of the 2 malignancies is rare and their coexistence raises the question of a common etiologic factor.
Case report
A 71-year-old man with no significant past medical history presented with an enlarged right cervical lymph node involved at levels IB and II. Examination in an ENT department characterized a fixed, hard, and nontender mass. Nasal endoscopy revealed right hypertrophy of the torus tubair (Fig. 1) . The patient underwent a neck computed tomography (CT) scan followed by positron emission tomography (PET-CT), which revealed a 3.8 Â 2.4 cm sized hypermetabolic mass with a maximum standardized uptake value of 28.32 on the right-sided nasopharynx and multiple ipsilateral enlarged lymph nodes with central cystic or necrotic portion on right level II. There were no active pulmonary parenchymal lesions in both lungs. A nasopharyngeal mass punch biopsy led to a diagnosis of DLBCL, not otherwise specified, with germinal center B-cell immunophenotype. According to the Ann Arbor system [8] , the patient was classified with stage IIE. He was treated with a course of 6 cycles of combination chemotherapy. His symptoms resolved within a couple of months after treatment. He was checked with PET-CT after 3 cycles and after the last cycle of treatment, which always defined no demonstrable fluoro-deoxyglucose (FDG)-avid residual lymphoma. He was followed up every 3 months for 1 year with radiological examinations, which showed no evidence of FDG-avid recurred lymphoma.
A follow-up PET-CT study at 18 months after chemotherapy for lymphoma (Fig. 2) revealed hypermetabolic thickening and an obliteration at the right Rosenmüller fossa. Nasal endoscopy revealed a protrusion on the posterolateral wall of the nasopharynx. Neck CT showed a mildly enhanced mass on posterolateral wall of the nasopharynx. Our first impression was recurred lymphoma. A punch biopsy was done. Histopathological findings confirmed a nasopharyngeal nonkeratinizing carcinoma, undifferentiated (World Health Organization type 3). According to the American Joint Committee on Cancer Staging, the patient was diagnosed with stage I (T1N0) nasophayngeal carcinoma. Laboratory tests were positive CD20 on B-cell and positive reactions for BCL-2, BCL-6, and EBV encoded small RNA. The patient was offered a course of cisplatin-based chemotherapy with radiation therapy. The nasopharynx mass was completely resolved after chemoradiation therapy. A patient was informed of the right to abstain from participation in the study and was not found to be ethically incompetent. We reviewed an institutional review board approval from Chonbuk National University Hospital and obtained proper consent from a patient (Fig. 3) .
Discussion
Only 3 cases of NPC and Hodgkin's lymphoma occurring in the same patients have been reported, either separated by several years (2 and 8 years), or concurrently at diagnosis. [4] To the best of our knowledge, we report here the 1st case of the occurrence of 2 cancers: a patient with DLBCL followed by NPC almost 2 years later.
EBV is an omnipresent ɤ-herpes virus that infects the majority of the human population by adulthood. [5] It is transmitted through saliva, infecting oropharyngeal epithelial cells, and Blymphocytes, and results in life-long persistence of the viral genome. The virus initially give rise to the lytic form of infection and then to the latent form of infection. The EBV latent proteins are important in mediating transformation and promoting oncogenesis. [6] The underlying pathogenesis for EBV-related cancers has not been completely defined, but appears to be mediated through activation of various cell signaling pathways by EBV nuclear antigens and latent membrane proteins. Indeed, an association has been found between the malignancies and the different types of latent EBV expression profiles in which they develop. A type I latency pattern is typical of Burkitt lymphoma, type II is seen in NPC and HL, [5] and type III is seen in DLBCL. [7] DLBCL is the most common subtype of malignant lymphoma accounting for 30% to 40% of new lymphoma cases, and only 40% to 50% of patients achieve durable remissions. Over 30% of DLBCL will ultimately relapse. [8] The role of EBV infection in pathogenesis of DLBCL is not known. EBV can infect resting B lymphocytes efficiently and drive it out of the resting state to become an activated lymphoblastoid cell line. These transforming effects are associated with the restricted expression of the EBVencoded latent genes, such as latent infection membrane protein 1. [8, 9] DLBCL harboring EBV positive monoclonal B-cell proliferation in patients older than 50 years of age without any known immunodeficiency. [9] Genetic factors could also play a role in the development of EBV-associated lymphoma. [10] NPC presents as an epithelial cancer with histology that ranges from well-differentiated to undifferentiated squamous cell carcinoma, and includes both keratinizing and nonkeratinizing forms. [6, 11] The disease is rare in the United States and Europe, but is endemic to parts of China and elsewhere in Asia. [5] The undifferentiated variant of NPC is universally associated with EBV infection, [3] viral genomes within the tumor are clonal and exhibit EBV gene products typical of a type II latency pattern.
This study describes a patient with DLBCL followed by NPC almost 2 years later. The presentation with DLBCL and NPC raises the possibilities of dual EBV infection or a different oncogenic mechanism. Human epithelial cells can be infected in vitro through the formation of specialized B cell-epithelial cell conjugates involving the GP350 EBV viral envelope glycoprotein and the CR2 receptor of B lymphocytes. This cell-to-cell method of EBV infection of nasopharyngeal epithelium may take place in vivo. EBV-infected B cells invariably may be present in the nasopharyngeal mucosa and can come into close contact with the polarized nasopharyngeal epithelial cells to transmit EBV. [1] In the present case, the serologic results revealed positive CD20 on B-cell and Epstein-Barr encoding region positive, illustrating a type III latency pattern.
Conclusion
Our observations support the possibility of multiple EBV infections in a single patient, which can lead to distinct malignancies. Since the 2 tumors in the same patient will contain different clonal viral genomes, it suggests that the 2 different EBV strains could activate different oncogenic pathways, leading to the occurrence of malignancies of lymphoid and epithelial cell origin, respectively. Further evaluation of EBV protein expression and cellular immune response in this patient could lend additional insight into the development of EBV-associated neoplasia.
